Sign inJoin waitlistJoin the waitlist

Deric Savior

Physician · Lankenau Medical Center

Credentials: · · ·

History

Lankenau Medical Center
2022–Present

Hematology and Medical Oncology
Lankenau Medical Center
2009–2012
National Rehabilitation Hospital
2005–2009
Graduate Hospital
2002–2005
HAHNEMANN UNIV SCH OF MED, PHILADELPHIA
1998–2002
Hampton University in Virginia

Research

The impact of the multidisciplinary tumor board on head and neck cancer outcomes
The Laryngoscope · 2020 · 70 citations
Full-term pregnancy and vaginal delivery after treatment for non-Hodgkin's lymphoma of the cervix and lower uterine segment: a case report
Case report · Journal of Obstetrics and Gynaecology Canada · 2011 · 7 citations
Assessing Guideline-Directed Care in the New Era of Neoadjuvant Therapy in Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): A Retrospective Review
Clinical Lung Cancer · 2026

AM
Alisha Maity
2 papers · 2 as a fellow
Arezoo Ghaneie
2 papers
Paul Gilman
2 papers
Aarti Shevade
1 paper
AK
Adam Kaplon
1 paper · 1 as a resident
Akshar Kalola
1 paper · 1 as a fellow
Curtis Miyamoto
1 paper
Erik Zeger
1 paper
Jeffrey Liu
1 paper
Kathleen Lamb
1 paper · 1 as a resident
Matthew Sanborn
1 paper · 1 as a resident
MP
Mohamad Parva
1 paper · 1 as a resident

Clinical trials

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2039
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2039
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2036
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2027